RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers.
Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫抑制性肿瘤微环境(TME)促进癌症进展,但癌症所携带的免疫指令的总体决定因素仍不明确。通过单核和批量转录组学、蛋白质组学、功能方法及临床参数的多模态整合,我们在多种人类癌症中发现了一种癌症免疫指令性分泌特征(CISS)——一组与不良预后和促肿瘤TME相关的炎症蛋白。在胰腺癌(PC)中,CISS起源于癌前上皮,在向最具恶性的基底样PC转化过程中增强,尤其与自然杀伤(NK)细胞活性受抑制相关。CISS在数量上由金属蛋白酶组织抑制剂(TIMP)-1主导,在TIMP-1 hi /CISS hi 基底样PC中最为普遍,并且是PC细胞介导NK细胞抑制的因果因素,表现为细胞毒性、白细胞介素-2(IL-2)反应和哺乳动物雷帕霉素靶蛋白(mTOR)信号传导受损。在临床前PC中,TIMP-1/CISS被证明可通过上游激酶联合抑制及临床批准药物trametinib和nintedanib进行靶向。
总体而言,CISS代表了一种普遍存在的促肿瘤免疫指令特征,在人类癌症中具有可操作的诊断和治疗潜力。
The immunosuppressive tumor microenvironment (TME) fosters cancer progression, yet overarching determinants of cancer-borne immunoinstruction remain ill-defined. By multimodal integration of single-nucleus and bulk transcriptomics, proteomics, functional approaches, and clinical parameters, we discover a cancer-immunoinstructive secretory signature (CISS) across multiple human cancers-a set of inflammatory proteins correlated with poor prognosis and pro-tumorigenic TMEs. In pancreatic cancer (PC), CISS arises in pre-malignant epithelium, intensifies along transformation toward most malignant basal-like PC, and particularly correlates with suppressed natural killer (NK) cell activity.
The CISS is quantitatively dominated by tissue inhibitor of metalloproteinases (TIMP)-1, most prevalent in TIMP-1 hi /CISS hi basal-like PC, and causal for PC-cell-mediated NK cell suppression, reflected by impaired cytotoxicity, interleukin-2 (IL-2) responses, and mammalian target of rapamycin (mTOR) signaling.
In pre-clinical PC, TIMP-1/CISS proves targetable through combined inhibition of upstream kinases with clinically approved drugs trametinib and nintedanib. Collectively, CISS represents a ubiquitous signature of pro-tumor immunoinstruction with actionable diagnostic and therapeutic potential across human cancers.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。